GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS Great Novel Therapeutics Biotech & Medicals Share Price
Equities
7427
TW0007427007
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52 TWD | -5.28% |
|
+8.56% | -22.16% |
| Sales 2022 | 540K 16.69K 1.39M | Sales 2023 | 4.85M 150K 12.52M | Capitalization | 2.56B 79.18M 6.61B |
|---|---|---|---|---|---|
| Net income 2022 | -55M -1.7M -142M | Net income 2023 | -61M -1.89M -157M | EV / Sales 2022 | 2,918 x |
| Net cash position 2022 | 248M 7.65M 639M | Net cash position 2023 | 463M 14.3M 1.19B | EV / Sales 2023 | 433 x |
| P/E ratio 2022 |
-27.2
x | P/E ratio 2023 |
-39.3
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.28% | ||
| 1 week | +8.56% | ||
| Current month | +7.22% | ||
| 1 month | +4.21% | ||
| 3 months | +10.29% | ||
| 6 months | -23.53% | ||
| Current year | -22.16% |
1 week
47.50
55.20
1 month
46.6055.20
Current year
44.5569.40
1 year
44.55108.00
3 years
30.85110.50
5 years
30.85110.50
10 years
30.85110.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Nan Chen
CEO | Chief Executive Officer | - | 03/13/03 |
Ying Chang Huang
DFI | Director of Finance/CFO | - | 04/21/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hung Jen Wu
BRD | Director/Board Member | - | 26/13/26 |
Chung Yang Huang
BRD | Director/Board Member | - | 02/17/02 |
Tien Tzu Tseng
BRD | Director/Board Member | - | 14/21/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 52 | -5.28% | 149,985 |
| 20/24/20 | 54.9 | +1.29% | 272,436 |
| 19/24/19 | 54.2 | +8.40% | 293,160 |
| 18/24/18 | 50 | +4.17% | 101,467 |
| 17/24/17 | 48 | +0.21% | 99,778 |
End-of-day quote Taipei Exchange, June 21, 2024
More quotes
GNT Biotech & Medicals Corp is a Taiwan-based company mainly engaged in the research, development and clinical trials of oral anti-cancer targeted new drugs. The main product is the oral anti-cancer targeted new drug TM/Kepida, which is mainly used for the treatment of relapsed and refractory peripheral T-cell lymphoma (R/R PTCL) and ER+/Her-2-advanced breast cancer (ER+/Her-2-BC). The Company is also engaged in the research and development of tumor immunotherapies. The products include GNTbm-CC-01 and GNTbm-CC-02, which are tumor microenvironment regulator new drug combinations, as well as GNTbm-38, which is surface immunomodulator.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.16% | 61.78M | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +34.92% | 38.48B | |
| +12.62% | 26.36B | |
| -12.11% | 26.22B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- 7427 Stock
